Stoke Therapeutics, Inc.: updates and filings

STOKNASDAQHealthcare · Pharmaceutical Preparations

Price

$26.93

November 19, 2026Market cap $1.8B

What Ploutos Investor adds for Stoke Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 4 fiscal years, from 2022
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 76 daysAround Feb 3, 2027 · for Q4 2026

last Oct 29, 2026next Feb 3, 2027

An estimate from when it has reported before, which has been regular. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 16, 2026 latest annualNov 3, 2026 latest quarterly
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 13, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 5, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 3, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Oct 29, 2026Results of operations
    Form8-K
  • Sep 30, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Sep 25, 2026Officer or director change
    Form8-K
  • Aug 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 12, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 6, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 3, 2026Other material events
    Form8-K
  • Aug 3, 2026Shares registered for employees
    FormS-8
  • Aug 3, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 3, 2026Results of operations
    Form8-K
  • Jun 30, 2026Regulation FD disclosure, other material events
    Form8-K
  • Jun 4, 2026Shareholder vote
    Form8-K
  • May 18, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 15, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 15, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 15, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 15, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 15, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • May 7, 2026Results of operations
    Form8-K

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Nov 24, 2014.

The full analysis

What do Stoke Therapeutics's filings show?

The filings are where every one of Stoke Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.